The National Cancer Institute (NCI) awarded a $216,682 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, to develop a protein therapeutic that can limit the transformation of endogenous anti-tumor autoantibodies into highly potent T cell-redirecting autoantibodies (TRABs). This project aims to optimize the engineered protein to restrict the TRABs to the tumor microenvironment and determine their distribution and therapeutic efficacy. The goal is to leverage a patient's own anti-tumor autoantibodies to direct T cells to attack cancer cells more effectively than current single-target bispecific antibody approaches. The award period is from March 1, 2025 to February 28, 2027.
Generated 3/18/25, 5:05 AM